Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(Phenylamino)pyrazolo[3,4-d]pyrimidines

Journal of Medicinal Chemistry

Volumn 40, Issue 22, 1997, Pages 3601-3616

  Traxler, Peter ^a   Bold, Guido ^a   Frei, Joerg ^a   Lang, Marc ^a   Lydon, Nicholas ^a   Mett, Helmut ^a   Buchdunger, Elisabeth ^a   Meyer, Thomas ^a   Mueller, Marcel ^a   Furet, Pascal ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(3 CHLOROPHENYL)AMINO] 1H PYRAZOLO[3,4 D]PYRIMIDINE; 3,4 BIS[(3 CHLOROPHENYL)AMINO] 1H PYRAZOLO[3,4 D]PYRIMIDINE; 4 (PHENYLAMINO)PYRAZOLO[3,4 D]PYRIMIDINE DERIVATIVE; DRUG CARRIER; ENZYME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BIOAVAILABILITY; CELL PROLIFERATION; COMPETITIVE INHIBITION; DRUG DESIGN; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; LIGAND BINDING; NONHUMAN; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DRUG DESIGN; ENZYME INHIBITORS; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICE; MICE, INBRED BALB C; MODELS, CHEMICAL; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 9844235351     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970124v     Document Type: Article

References (43)

1. Aaronson, S. A. Growth Factors and Cancer. Science 1991, 254, 1146-1152.
2. Ullrich, A.; Schlessinger, J. Signal Transduction by Receptors with Tyrosine Kinase Activity. Cell 1990, 61, 203-212.
3. Elder, J. T.; Fisher, G. J.; Lindquist, P. B.; Bennett, G. L.; Pittelkow, M. R.; Coffey, R. J.; Ellingsworth, L.; Derynck, R.; Voorhees, J. J. Overexpression of transforming growth factor α in psoriatic epidermis. Science 1989, 243, 811-814.
4. Burke, T. R. Protein-Tyrosine Kinase Inhibitors. Drugs Future 1992, 17, 119-131.
5. Fry, D. W. Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors. Exp. Opin. Invest. Drugs 1994, 3 (6), 577-595.
6. Levitzki, A.; Gazit, A. Tyrosine Kinase Inhibition: An Approach to Drug Development. Science 1995, 267, 1782-1788.
7. Traxler, P.; Lydon, N. Recent Advances in Protein Tyrosine Kinase Inhibitors. Drugs Future 1995, 20 (12), 1261-1274.
8. Spada, A. P.; Myers, M. R. Small molecule inhibitors of tyrosine kinase activity. Exp. Opin. Ther. Pat. 1995, 5, 805-817.
9. Bridges, A. J. The current status of tyrosine kinase inhibitors: do the diarylamine inhibitors of the EGF receptor represent a new beginning? Exp. Opin. Ther. Pat. 1995, 5 (12), 1245-1257.
10. Trinks, U.; Buchdunger, E.; Furet, P.; Kump, W.; Mett, H.; Meyer, Th.; Muller, M.; Re-genass, U.; Rihs, G.; Lydon, N.; Traxler, P. Dianilinophthalimides: Potent and Selective, ATP-Competitive Inhibitors of the EGF-Receptor Protein Tyrosine Kinase. J. Med. Chem. 1994, 37, 1015-1027.
11. Buchdunger, E.; Trinks, U.; Mett, H.; Regenass, U.; Müller, M.; Meyer, Th.; McGlynn, E.; Pinna, L. A.; Traxler, P.; Lydon, N. B. 4,5-Dianilinophthalimide: A protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 2334-2338.
12. Buchdunger, E.; Trinks, U.; Mett, H.; Regenass, U.; Müller, M.; Meyer, Th.; Beilstein, P.; Wirz, B.; Schneider, P.; Traxler, P.; Lydon, N. B. 4,5-Bis(4-fluoroanilino)-phthalimide: a selective inhibitor of the EGF receptor signal transduction pathway with potent in vivo antitumor activity. Clin. Cane. Res. 1995, 1, 813-821.
13. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, Th.; Müller, M.; Regenass, U.; Lydon, N. B. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2558-2562.
14. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, Th.; Müller, M.; Druker, B. J.; Lydon, N. B. Inhibition of the Abl Protein-Tyrosine Kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996, 56, 100-104.
15. Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 1996, 2, 561-566.
16. Barker, A. J.; Davies, D. H. European Patent Application (Zeneca) Nr. 0 520 722 A-1, December 30, 1992. Barker, A. J. European Patent Application (Zeneca) Nr. 0 566 226 A-1, October 20, 1993.
17. Barker, A. J.; Davies, D. H. European Patent Application (Zeneca) Nr. 0 520 722 A-1, December 30, 1992. Barker, A. J. European Patent Application (Zeneca) Nr. 0 566 226 A-1, October 20, 1993.
18. Barker, A. J.; Brown, D. S. European Patent Application (Zeneca) Nr. 602 851 A-1, 1993. Barker, A. J. European Patent Application (Zeneca) Nr. 635 498 A-1, 1994, Barker, A. J. European Patent Application (Zeneca) Nr. 635 507 A-1, 1994.
19. Barker, A. J.; Brown, D. S. European Patent Application (Zeneca) Nr. 602 851 A-1, 1993. Barker, A. J. European Patent Application (Zeneca) Nr. 635 498 A-1, 1994, Barker, A. J. European Patent Application (Zeneca) Nr. 635 507 A-1, 1994.
20. Barker, A. J.; Brown, D. S. European Patent Application (Zeneca) Nr. 602 851 A-1, 1993. Barker, A. J. European Patent Application (Zeneca) Nr. 635 498 A-1, 1994, Barker, A. J. European Patent Application (Zeneca) Nr. 635 507 A-1, 1994.
21. Ward, W. H. J.; Cook, P. N.; Slater, A. M.; Davies, D. H.; Holdgate, G. A.; Green, L. R. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 1994, 48 (4), 659-666.
22. Fry, D. W.; Kraker, A. J.; McMichael, A.; Ambrose, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosne Kinase. Science 1994, 265, 1093-1095.
23. Myers, M. R.; Spada, A. P.; Maguire, M. P.; Persona, P. E. Patent Application (Rorer-Rhone-Poulenc) WO 9 515 758-A1, 1995.
24. Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Zhou, H.; Cody, D. R.; McMichael, A.; Fry, D. W. Tyrosine Kinase Inhibitors. 5. Synthesis and Structure-Activity Relationships for 4-(Phenylmethyl-aminol-and 4-(Phenylamino)quinazolines as Potent Adenosine 5′-Triphosphate Binding Site Inhibitors of the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor. J. Med. Chem. 1995, 38, 3482-3487.
25. Rewcastle, G. W.; Palmer, B. D.; Bridges, A. J.; Showalter, H. D.; Sun, L.; Nelson, J. M.; McMichael, A.; Kraker, A. J.; Fry, D. W.; Denny, W. A. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazolines analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 918-928.
26. Thompson, A. M.; Bridges, A. J.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine Kinase Inhibitors. 7. 7-Amino-4-(phenylamino)-and 7-Amino-4-[(phenylmethyl)amino-lpyrido[4,3-d]pyrimidines: A New Class of Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor. J. Med. Chem. 1995, 38, 3780-3788.
27. Rewcastle, G. W.; Palmer, B. D.; Thompson, A. M.; Bridges, A. J.; Cody, D. R.; Zhou, H.; Fry, D. W.; McMichael, A.; Kraker, A. J.; Denny, W. A. Tyrosine Kinase Inhibitors. 10. Isomeric 4-[(3-bromophenyl)-amino]-pyrido[d]-pyrimidines are potent ATP binding site, inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 1823-1835.
28. Traxler, P.; Furet, P.; Mett, H.; Buchdunger, E.; Meyer, T.; Lydon N. 4-(Phenylamino)pyrrolopyrimidines: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase. J. Med. Chem. 1996, 38, 2285-2292.
29. Furet, P.; Caravatti, G.; Lydon, N.; Priestle, J.; Sowadski, J.; Trinks, U.; Traxler, P. Modeling Study of Protein Kinase Inhibitors: Binding Mode of Staurosporine - Origin of the Selectivity of CGP 52 411. J. Comput.-Aided Mol. Des. 1995, 9, 465-471.
30. 28
31. Knighton, D. R.; Cadena, D. L.; Zheng, J.; Ten Eyck, L. F.; Taylor, S. S.; Sowadski, J. M.; Gill, G. N. Structural Features that Specify Tyrosine Kinase Activity Deduced from Homology Modeling of the Epidermal Growth Factor Receptor. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 5001-5005.
32. Zheng, J.; Knighton, D. R.; Ten Eyck, L. F.; Karlsson, R.; Xuong, N. H.; Taylor, S. S.; Sowadski, J. M. Crystal Structure of the Catalytic Subunit of c AMP- Dependent Protein Kinase Complexed with MgATP and Peptide Inhibitor. Biochemistry 1993, 32, 2154-2161.
33. Dow, R.; Koch, K.; Schulte, G. Patent Application (Pfizer Inc.) US5593997, 1997.
34. Hanke, J. H.; Gardner, J. P.; Dow, R. L.; Changelian, P. S.; Brissette, W. H.; Weringer, E. J.; Pollok, B. A.; Connelly, P. A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. J. Biol. Chem. 1996, 271, 695-701.
35. Tominaga, Y.; Honkawa, Y.; Hara, M.; Hosomi, A. Synthesis of Pyrazolo[3,4-d]pyrimidine Derivatives Using Ketene Dithioacetales. J. Heterocycl. Chem. 1990, 27, 775-783.
36. Sasho, S.; Obase, H.; Harakawa, H.; Ichikawa, S.; Kitazawa T.; Kishibayashi, N.; Yokoyama, T.; Nonaka, H.; Yoshizaki, R.; Ishii, A.; Shuto, K. Synthesis of 2-Imidazo-lidinylidene Propanedinitrile Derivatives as Stimulators of Gastrointestinal Motility Bioorg. Med. Chem. 1994, 2 (10), 1107-1117.
37. Tominaga, Y.; Matsuoka, Y.; Oniyama, Y.; Uchiraura, Y.; Komiya H.; Hirayama, M.; Kohra, S.; Hosomi, A. Synthesis of Polarized Ethylenes Using Thioamides and Methyl Dithiocarboxylates and Their Application to Synthesis of Pyrazoles, Pyrimidines, Pyrazolo[3,4-d]pyrimidines, and 5-Aza[2.2.3]cyclazines. J. Heterocycl. Chem. 1990, 27, 647-660.
38. Palmer, B. D.; Trumpp-Kallmeyer, S.; Fry, D. W.; Nelson, J. M.; Showalter H. D. H.; Denny, W. A. Tyrosine Kinase Inhibitors. 11. Soluble Analogues of Pyrrolo- and Pyrazoloquinazolines as Epidermal Growth Factor Receptor Inhibitors: Synthesis, Biological Evaluation, and Modeling of the Mode of Binding. J. Med. Chem. 1997, 40, 1519-1529.
39. Schulze-Gahmen, U.; Brandsen, J.; Jones, H. D.; Morgan, D. O.; Meijer, L.; Vesely, J.; Kim, S. H. Multiple Modes of Ligand Recognition: Crystal Structures of Cyclin-Dependent Protein Kinase 2 in Complex with ATP and Two Inhibitors, Olomoucine and Isopentenyladenine. Proteins 1995, 22, 378-391.
40. Schulze-Gahmen, U.; De Bondt, H. L., Kim, S. H. High Resolution Crystal Structures of Human Cyclin-Dependent Kinase 2 with and without ATP: Bound Waters and Ligand as Guides for Inhibitor Design. J. Med. Chem. 1996, 39, 4540-4546.
41. Meyer, T.; Regenass, U.; Fabbro, D.: Alten, E.; Roesel, J.; Mueller, M.; Caravatti, G.; Matter, A. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro proliferative as well as in vivo anti-tumor activity. Int. J. Cancer 1989, 43, 851-856.
42. Alonso, G.; Alvarez-Ibarra, C.; Orellana, G.; Quiroga, M. L. Synthesis of 5-Aryl- and 5-Alkyl-4-Ethoxycarbonyl-2-Methylthio1,3-Thiazoles from Dimethyl N-(Ethoxy-carbonylmethyl)Iminodithiocarbonate and Dithioesters. Bull. Soc. Chim. Belg. 1989, 98, 215-219.
43. Thiel, W.; Mayer, R. Dithiocarbonsäuren, Dithiocarbonsäureester oder Thiocarbon-säureamide aus methylenaktiven Chlormethylverbindungen und Schwefel. (Dithiocarboxylic acids, Dithiocarboxylic acid esters or Thiocarboxylic acid amides from methylene activated chloromethyl derivatives and sulfur.) J Prakt. Chem. 1989, 331, 243-262.